Drugs / ASP6981
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03356639 | Jan → May 2018 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP6981 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03356639 ↗ |
| Route | Oral | “ASP6981 capsules orally (50 mg)” NCT03356639 ↗ |